Trends in liver transplantation for autoimmune liver diseases: a Canadian study

Background: To our knowledge, no analysis of data from liver transplantation registries exists in Canada. We aimed to describe temporal trends in the number of liver transplantation procedures, patient characteristics and posttransplantation outcomes for autoimmune liver diseases (AILDs) in Canada. Methods: We used administrative data from the Canadian Organ Replacement Register, which contains liver transplantation information from 6 centres in Canada. This study included transplantation information from 5 of the centres, as liver transplantation procedures in children were not included. We included adult (age ≥ 18 yr) patients with a diagnosis of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH) or overlap syndrome (PBC–AIH or PSC–AIH) who received a liver transplant from 2000 to 2018. Results: Of 5722 primary liver transplantation procedures performed over the study period, 1070 (18.7%) were for an AILD: 489 (45.7%) for PSC, 341 (31.9%) for PBC, 220 (20.6%) for AIH and 20 (1.9%) for overlap syndrome. There was a significant increase in the absolute number of procedures for PSC, with a yearly increase of 0.6 (95% confidence interval 0.1 to 1.2), whereas the absolute number of procedures for PBC and AIH remained stable. The proportion of transplantation procedures decreased for PBC and AIH but remained stable for PSC. Recipient age at transplantation increased over time for males with PBC (median 53 yr in 2000–2005 to 57 yr in 2012–2018, p = 0.03); whereas the median age among patients with AIH decreased, from 53 years in 2000–2005 to 44 years in 2006–2011 (p = 0.03). The Model for Endstage Liver Disease score at the time of transplantation increased over time for all AILDs, particularly AIH (median 16 in 2000–2005 v. 24 in 2012–2018, p < 0.001). There was a trend toward improved survival in the PBC group, with a 5-year survival rate of 81% in 2000–2005 and 90% in 2012–2018 (p = 0.06). Conclusion: Between 2000 and 2018, the absolute number of liver transplantation procedures in Canada increased for PSC but remained stable for PBC and AIH; proportionally, PBC and AIH decreased as indications for transplantation. Posttransplantation survival improved only for the PBC group. An improved understanding of trends and outcomes on a national scale among patients with AILD undergoing liver transplantation can identify disparities and areas for potential health care improvement.

[1]  K. Zieniewicz,et al.  Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry , 2020, Transplantation.

[2]  F. Carrat,et al.  Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. , 2020, Journal of hepatology.

[3]  K. Zieniewicz,et al.  Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  A. Bonder,et al.  Increased Posttransplant Mortality for Autoimmune Hepatitis Compared With Other Autoimmune Liver Diseases , 2019, Journal of clinical gastroenterology.

[5]  K. Kang,et al.  Allocation of Liver Grafts Worldwide Is there a best System? , 2019, Journal of hepatology.

[6]  N. Kneteman,et al.  Canadian liver transplant allocation for hepatocellular carcinoma. , 2019, Journal of hepatology.

[7]  F. Nevens,et al.  Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. , 2019, Journal of hepatology.

[8]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  K. Zieniewicz,et al.  Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades , 2018, Alimentary pharmacology & therapeutics.

[10]  Amélie Quesnel-Vallée,et al.  Canada's universal health-care system: achieving its potential , 2018, The Lancet.

[11]  C. Bowlus,et al.  Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update , 2016, Journal of managed care & specialty pharmacy.

[12]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[13]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[14]  D. Raptis,et al.  The model for end‐stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  S. Friedman,et al.  Transplantation trends in primary biliary cirrhosis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.